Equativ Launches Media Planning Agent to Enhance Buyer Efficiency and Boost Campaign Outcomes Leave a reply Built on Maestro by Equativ, this is the first of a full suite of Equativ AI Agents for buyers that simplifies media planning, drives smarter decisions, higher ROAS, and scalable performance. NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) — Equativ, the leading independent media platform,

Equativ Launches Media Planning Agent to Enhance Buyer Efficiency and Boost Campaign Outcomes Leave a reply Built on Maestro by Equativ, this is the first of a full suite of Equativ AI Agents for buyers that simplifies media planning, drives smarter decisions, higher ROAS, and scalable performance. NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) — Equativ, the leading independent media platform,

Equativ Launches Media Planning Agent to Enhance Buyer Efficiency and Boost Campaign Outcomes Leave a reply Built on Maestro by Equativ, this is the first of a full suite of Equativ AI Agents for buyers that simplifies media planning, drives smarter decisions, higher ROAS, and scalable performance. NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) — Equativ, the leading independent media platform,

Equativ Launches Media Planning Agent to Enhance Buyer Efficiency and Boost Campaign Outcomes Leave a reply Built on Maestro by Equativ, this is the first of a full suite of Equativ AI Agents for buyers that simplifies media planning, drives smarter decisions, higher ROAS, and scalable performance. NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) — Equativ, the leading independent media platform,

Equativ Launches Media Planning Agent to Enhance Buyer Efficiency and Boost Campaign Outcomes Leave a reply Built on Maestro by Equativ, this is the first of a full suite of Equativ AI Agents for buyers that simplifies media planning, drives smarter decisions, higher ROAS, and scalable performance. NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) — Equativ, the leading independent media platform,

Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season Leave a reply Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season VICTORIA, Seychelles, Dec. 09, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), has released new

Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season Leave a reply Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season VICTORIA, Seychelles, Dec. 09, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), has released new

Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season Leave a reply Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season VICTORIA, Seychelles, Dec. 09, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), has released new

Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season Leave a reply Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season VICTORIA, Seychelles, Dec. 09, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), has released new

Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy Leave a reply RICHARDSON, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mavenir, the software company building AI-by-design mobile networks, today announced a strong leadership team to accelerate its vision for telco-first, cloud-native, AI-by-design networks. This transformation follows the company’s recent recapitalization

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks Leave a reply REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12

Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober VICTORIA, Seychelles, Dec. 08, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), today released its October 2025 Protection Fund report, recording an average monthly valuation of $741,435,710 despite a challenging month across digital asset markets. The fund

EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025 Leave a reply Recognition follows a vote by professional and active traders, highlighting the critical role of execution quality in institutional-grade trading Best Broker for Execution at the Professional Trader Awards 2025 – EBC Financial Group Christopher Potts, Chief Operating Officer & Chief Technology Officer, EBC

Private Healthcare Costs Are Rewriting the Map for Migrating Millionaires, New Data Shows Leave a reply LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — A sharp acceleration in global wealth migration in 2025 is colliding with rapidly diverging private healthcare costs worldwide, making the availability and costs of reliable private care a decisive factor in where high-net-worth families choose to live,

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting Leave a reply DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients.